Abintus is developing novel, off-the-shelf genetic medicines that reprogram cells directly in vivo to improve patient outcomes and access. These therapies are based on the Abintus Modular Viral Platform (MVP) and have the potential to reprogram any cell type in the body and target a range of diseases. The company’s initial In Vivo CAR-X products are designed to simultaneously reprogram both innate and adaptive immune effecto...
Abintus is developing novel, off-the-shelf genetic medicines that reprogram cells directly in vivo to improve patient outcomes and access. These therapies are based on the Abintus Modular Viral Platform (MVP) and have the potential to reprogram any cell type in the body and target a range of diseases. The company’s initial In Vivo CAR-X products are designed to simultaneously reprogram both innate and adaptive immune effector cells and produce potent and durable immune responses against hematologic malignancies and solid tumors.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.